ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond UCSF Criteria: Tumor Biology Not the Tumor Number Decide the Long Term Outcome- A Single Center Retrospective Analysis of Using Extended Criteria

A. Thorat, L. Jeng, S. Hsu, H. Yang, P. Li, T. Chen, K. Poon

Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan

Meeting: 2020 American Transplant Congress

Abstract number: A-152

Keywords: Hepatocellular carcinoma, Living-related liver donors, Tumor recurrence

Session Information

Session Name: Poster Session A: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: HCC is the fifth most common cancer and the third most frequent cause of cancer deaths worldwide. After its introduction for LT in HCC patients, Milan’s criteria were universally validated and, also, was accepted as allocation criteria of UNOS in 2001 & Eurotransplantation in 2006. However, due to restrictive nature of the Milan’s criteria and ever-increasing HCC patient cohort, UCSF criteria was introduced which was first modest attempt to expand the criteria. In this study, we present our experience of LDLT for HCC patients beyond the UCSF criteria.

*Methods: From September 2002 to August 2019, a total of 1054 LDLT surgeries were performed at China Medical University Hospital, Taiwan. Database of the 469 patients of HCC that underwent LDLT was analysed and patients with HCC beyond the UCSF criteria were (n=147) were further studied for long-term outcome. 56 patients with AFP levels < 1000 ng/ml were further studied for the histopoatholgical characteristics. The patients were further categorized as per the degree of differentiation of the tumor on histopathological examination (HPE), vascular invasion and AFP levels- Group A (G1-G2/Macro(-)/AFP<100) and Group B (G3-G4/Macro(+)/AFP>100)

*Results: 147 patients (31.3%) had the HCC beyond the criteria whereas 322 patients (68.7%) were within UCSF criteria. 5-overall survival achieved in patients beyond UCSF was 45.7% versus 74.65% 5-year survival for patients within UCSF criteria. The study cohort was further categorized depending upon the degree of differentiation of HCC. 5-year survival for Group A HCC patients was 83% whereas the outcome was inferior in Group HCC patients with a 5-year survival rate of 21.68% (Figure 1). Patients with AFP >1000 ng/ml showed a dismal prognosis with a 5-year survival of < 21% patients.

 border=

*Conclusions: Extended criteria for HCC in LDLT can achieve a modest long-term survival. Features of biological tumor behavior, such as tumor grading and vascular invasion and high AFP levels have impact on recurrence of HCC after LDLT. Tumors with well differentiated morphology and AFP levels <100 ng/ml increases long-term survival even further.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Thorat A, Jeng L, Hsu S, Yang H, Li P, Chen T, Poon K. Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond UCSF Criteria: Tumor Biology Not the Tumor Number Decide the Long Term Outcome- A Single Center Retrospective Analysis of Using Extended Criteria [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/living-donor-liver-transplantation-for-hepatocellular-carcinoma-beyond-ucsf-criteria-tumor-biology-not-the-tumor-number-decide-the-long-term-outcome-a-single-center-retrospective-analysis-of-using-e/. Accessed May 9, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences